A. Mukaiyama

A phase I/Ib study of trametinib (GSK1120212) alone and in combination with gemcitabine in Japanese patients with advanced solid tumors

Toshio Shimizu, J. Furuse, H. Kitamura, 2015, Investigational New Drugs.

Degradation of Interleukin 1β by Matrix Metalloproteinases*

Y. Sasaguri, J. Enghild, Y. Itoh, 1996, The Journal of Biological Chemistry.

Interim safety analysis from TYTAN: A phase III Asian study of lapatinib in combination with paclitaxel as second-line therapy in gastric cancer.

Jianming Xu, K. Yeh, A. Ohtsu, 2010 .

Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study.

Y. Bang, K. Yeh, A. Ohtsu, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety, tolerability, and pharmacokinetic profile of dabrafenib in Japanese patients with BRAFV600 mutation-positive solid tumors: a phase 1 study

N. Yamazaki, T. Tamura, A. Tsutsumida, 2018, Investigational New Drugs.

Phase 1/2 study assessing the safety and efficacy of dabrafenib and trametinib combination therapy in Japanese patients with BRAF V600 mutation‐positive advanced cutaneous melanoma

N. Yamazaki, A. Tsutsumida, Y. Kiyohara, 2018, The Journal of dermatology.

Phase I and pharmacologic study of weekly bolus topotecan for advanced non-small-cell lung cancer.

M. Fukuoka, S. Kudoh, M. Takada, 2010, Clinical lung cancer.

Phase I dose-escalation and pharmacokinetic trial of lapatinib (GW572016), a selective oral dual inhibitor of ErbB-1 and -2 tyrosine kinases, in Japanese patients with solid tumors.

M. Fukuoka, H. Mukai, Y. Sasaki, 2008, Japanese journal of clinical oncology.

Phase I dose-escalation and pharmacokinetic trial of lapatinib (GW572016), a selective oral dual inhibitor of ErbB-1 and -2 tyrosine kinases, in Japanese patients with solid tumors.

M. Fukuoka, H. Mukai, Y. Sasaki, 2008, Japanese journal of clinical oncology.